Routine Screening for Mycoplasma genitalium Is NOT Recommended
Routine screening of asymptomatic individuals for Mycoplasma genitalium is not recommended, regardless of pregnancy status or sexual activity. Testing should be reserved for specific clinical scenarios only 1, 2.
When to Test for M. genitalium
Testing is appropriate ONLY in the following situations:
Symptomatic Patients
- Persistent or recurrent urethritis after standard treatment for gonorrhea/chlamydia 3, 1
- Cervicitis with clinical signs 1
- Pelvic inflammatory disease (PID) 1
- Proctitis 1
Asymptomatic Patients
- Sexual contacts of confirmed M. genitalium cases 1
Why Routine Screening Is Harmful
The evidence strongly argues against routine screening for several critical reasons:
Antibiotic overuse and resistance: When M. genitalium was included in standard STI panels, more than three times as many patients were inappropriately treated with antibiotics compared to selective testing 2. This directly contributes to the already severe macrolide resistance problem, with resistance-associated mutations now widespread 4, 5.
Unknown clinical significance in asymptomatic infection: The clinical impact of treating asymptomatic M. genitalium infection remains unknown 6, 1. While prevalence can be relatively high (8.7-14.6% in some populations) 4, 7, most asymptomatic cases may not require treatment.
Limited treatment options: M. genitalium lacks a cell wall, restricting treatment to macrolides, tetracyclines, and fluoroquinolones—all classes facing increasing resistance 5. Unnecessary treatment of asymptomatic cases accelerates resistance development.
Special Populations
Pregnant Patients
Do not screen asymptomatic pregnant patients unless they have documented exposure to M. genitalium 1. Despite a recent surge in consultations about M. genitalium detection in asymptomatic pregnant individuals 6, testing is not indicated without symptoms or known exposure.
High-Risk Populations
Even in populations with high rates of chlamydia and gonorrhea, routine M. genitalium screening is not recommended 2. The USPSTF guidelines for STI screening in high-risk women include chlamydia, gonorrhea, HIV, and syphilis—but not M. genitalium 8.
Common Pitfalls to Avoid
- Do not include M. genitalium in routine STI panels 2
- Do not test asymptomatic patients "just because" multiplex platforms include it 6
- Do not treat based on symptoms alone without documented urethral inflammation 3
- Recognize that co-infections are common (39.3% with chlamydia, 21.3% with gonorrhea) 7, so treat those organisms first before considering M. genitalium testing
Clinical Algorithm
- Patient presents with urogenital symptoms → Test for gonorrhea and chlamydia first
- Symptoms persist after appropriate treatment → Consider M. genitalium testing
- Patient has confirmed M. genitalium exposure → Test sexual contacts regardless of symptoms
- Asymptomatic patient requests STI screening → Do NOT include M. genitalium testing
This selective approach balances appropriate diagnosis of clinically significant infections while minimizing antibiotic overuse and resistance development 1, 2.